Breaking News Instant updates and real-time market news.

OTIC

Otonomy

$2.34

-0.07 (-2.90%)

21:35
11/14/18
11/14
21:35
11/14/18
21:35

Otonomy initiated with an Overweight at Cantor Fitzgerald

Price target $9.

  • 27

    Nov

OTIC Otonomy
$2.34

-0.07 (-2.90%)

08/14/18
RHCO
08/14/18
NO CHANGE
Target $10
RHCO
Buy
Otonomy price target lowered to $10 from $15 at SunTrust
SunTrust analyst Edward Nash lowered his price on Otonomy to $10 and kept his Buy rating, saying that while he remains bullish on the company's position in the "under-addressed neuro-otology space" after its initiated Phase 3 trial for Otividex, he also sees a "lack of near term catalysts". The analyst adds that the next "significant" even will come from the Otividex results in the first half of 2020, but notes that the stock is currently trading "near cash".
03/19/18
JPMS
03/19/18
DOWNGRADE
JPMS
Underweight
Otonomy downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama downgraded Otonomy to Underweight without a price target. The analyst sees "no true value drivers in 2018" with an additional third Phase 3 trial for Otividex in Meniere's disease needed for approval.
03/12/18
PIPR
03/12/18
UPGRADE
Target $11
PIPR
Overweight
Otonomy upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Charles Duncan upgraded Otonomy to Overweight and raised his price target for the shares to $11 from $8. The analyst believes the company has sufficient cash and a "clearly articulated" Phase 3 plan. He also believes little value is being accorded to Otividex's potential.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.